TONIX PHARMACEUTICALS HLDG C's ticker is TNXP and the CUSIP is 890260201. A total of 37 filers reported holding TONIX PHARMACEUTICALS HLDG C in Q3 2016. The put-call ratio across all filers is 16.09 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $36,000 | -53.8% | 76,500 | -31.8% | 0.00% | -60.0% |
| Q3 2016 | $78,000 | -77.7% | 112,200 | -36.2% | 0.01% | -81.5% |
| Q2 2016 | $350,000 | -21.9% | 175,905 | -5.4% | 0.03% | -15.6% |
| Q1 2016 | $448,000 | -72.7% | 185,975 | -13.1% | 0.03% | -68.9% |
| Q4 2015 | $1,642,000 | +14.9% | 214,125 | -20.7% | 0.10% | +1.0% |
| Q3 2015 | $1,429,000 | -55.9% | 270,075 | -25.3% | 0.10% | -48.2% |
| Q2 2015 | $3,243,000 | +63.3% | 361,575 | +15.1% | 0.20% | +64.2% |
| Q1 2015 | $1,986,000 | -4.8% | 314,170 | -12.1% | 0.12% | -7.7% |
| Q4 2014 | $2,086,000 | -22.0% | 357,250 | -8.5% | 0.13% | -22.6% |
| Q3 2014 | $2,675,000 | -27.0% | 390,550 | +53.0% | 0.17% | -22.9% |
| Q2 2014 | $3,663,000 | +23.0% | 255,250 | -10.8% | 0.22% | +10.7% |
| Q1 2014 | $2,978,000 | +60.6% | 286,100 | +59.1% | 0.20% | +68.4% |
| Q4 2013 | $1,854,000 | +1937.4% | 179,800 | +619.2% | 0.12% | +1850.0% |
| Q3 2013 | $91,000 | – | 25,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 392,952 | $4,051,000 | 0.53% |
| BLUESTEIN R H & CO LLC | 179,800 | $1,854,000 | 0.12% |
| Edge Wealth Management LLC | 15,000 | $154,000 | 0.07% |
| Tower Research Capital LLC (TRC) | 1,316 | $14,000 | 0.00% |
| VANGUARD GROUP INC | 37,190 | $384,000 | 0.00% |
| LADENBURG THALMANN FINANCIAL SERVICES INC. | 100 | $1,000 | 0.00% |
| UBS AG | 1,878 | $19,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 106 | $1,000 | 0.00% |
| FIRST MANHATTAN CO. LLC. | 2,500 | $25,000 | 0.00% |
| CREDIT SUISSE AG/ | 19,370 | $200,000 | 0.00% |